Phase 2/3 trial of maintenance lapatinib for HER1/2-positive metastatic bladder cancer
Development of novel treatments in melanoma patients with BRAF mutations
Immunotherapy news for skin cancer from WCCS/EADO 2016 congress
Center experience: immunotherapy at the Royal Marsden
Immunotherapy: will we reach a point where we can curatively treat advanced NSCLC?